Cullinan Therapeutics (CGEM) Leerink Global Healthcare Conference 2025 summary

Strategic evolution and pipeline expansion

• 2025 marks a key inflection point, with a pipeline of five clinical-stage assets targeting both cancer and autoimmune diseases.

• Expanded R&D into autoimmune diseases, notably with CLN-978, a CD19 by CD3 T-cell engager.

• Focus on restoring immune system balance, leveraging convergence of oncology and immunology.

• First to clear an IND in the U.S. for a development-stage CD19 T-cell engager, with global lupus studies ongoing and RA study initiation planned for Q2.

• Guidance for lupus data in Q4 and ongoing expansion into new indications.

Oncology pipeline and financial position

• Diversified oncology assets include CLN-619 (MICA/MICB antibody) and zipalertinib (EGFR exon 20 TKI), with recent positive data and upcoming milestones.

• Data readouts for endometrial and cervical cancer expected in Q2; NDA for zipalertinib planned for H2.

• Over $600 million in cash as of December, providing runway into 2028.

• Trading at or below cash value, with multiple near-term catalysts anticipated.

Partnership and commercialization strategy

• Partnership with Taiho includes $275 million upfront, $130 million in regulatory milestones, and a 50/50 U.S. profit share with co-commercialization option.

• Commercial infrastructure can be built cost-efficiently, leveraging Taiho's experience.

• Decision on co-commercialization option remains open, with ample time to decide.